Drug Database
Back to search

Iceland· IS-EU/1/04/285/005-012

Apidra

A insulin glulisine product containing insulinum glulisinum inn, registered in Iceland by Sanofi-Aventis Deutschland GmbH. The same ATC class is registered in 14 of our 19 countries.

ATC A10AB06

Checked against Icelandic Medicines Agency (Iceland) on

Informational only — not a medical device.

SOURCE REGISTER · ISIcelandic Medicines Agency (Iceland)normalisedApidraATCA10AB06REGISTER NO.IS-EU/1/04/285/005-012PACKS LISTED0CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about insulinum glulisinum innAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Insulin glulisine is registered in 14 of 19 countries.

Countries holding a registration under ATC A10AB06 (insulin glulisine), each read from that country’s own register.

  • This record: Iceland, from Icelandic Medicines Agency (Iceland)
  • 9 of them publish a price we can compare per daily dose
Search insulin glulisine products by name

Insulin glulisine · ATC A10AB06

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Icelandic Medicines Agency (Iceland)
Active substance
Insulinum glulisinum INN
Manufacturer
Sanofi-Aventis Deutschland GmbH
Country
Iceland (IS)
ATC code
A10AB06
ATC class
Insulin glulisine
Defined daily dose
40 E, P
Reimbursed
Not published by this register
Source register
Icelandic Medicines Agency (Iceland)
Last checked
September 29, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

434 interactions on record for insulin glulisine.

Graded by severity as the source publishes them — 15 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check insulin glulisine against other medicinesHow interaction checks work

Insulin glulisine · interactions on record

434 records

  • 15 severe
  • 368 moderate
  • 50 minor

Most severe, free to view

  • SucralfateA02BX02moderate
  • ThiethylperazinA04AB03moderate
  • TriflupromazinA04AD06moderate
  • PrednisoloneA07EA01moderate

1 more interaction with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Insulin glulisine in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All insulin glulisine products

Authorised across Europe · EMA

The same active substance is authorised in 2 EEA countries. Names it is sold under:

  • Liechtenstein · Apidra, Apidra Solostar
  • Norway · Apidra, Apidra Solostar

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/24134ae1-ac97-4c9e-8bdc-c2646c78f0c6
GET /v1/drugs/24134ae1-ac97-4c9e-8bdc-c2646c78f0c6?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Stungulyf, lausn í rörlykju",
  "source": "lyfjastofnun",
  "atc_raw": "A10AB06",
  "marketed": false,
  "strength": "100 ein./ml",
  "ma_number": "EU/1/04/285/005-012",
  "substance": "Insulinum glulisinum INN",
  "other_info": null,
  "legal_status": "(R) Lyfseðilsskylt",
  "ma_issued_serial": "38287"
}
API referenceMCP serverPlans

See everything about insulin glulisine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console